Mi a Novan, Inc. (NOVN piaci tőkésítése)

Novan, Inc. piaci tőkésítése (NOVN) $451.38K

Novan, Inc. (NOVN) Ár és Piaci Kapitalizáció

Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.

A NOVN ára	B aktíva	A B piaci tőkésítése	Eredmények
$678,576 $451.38K	NVDA	$5.470T	+1,211,742,781.38%
$554,205 $451.38K	AAPL	$4.467T	+989,652,399.15%
$517,894 $451.38K	GOOG	$4.174T	+924,809,850.85%
$459,049 $451.38K	MSFT	$3.700T	+819,729,559.49%
$354,123 $451.38K	AMZN	$2.854T	+632,362,192.30%

A NOVN ára

B aktíva

A B piaci tőkésítése

Eredmények

$678,576 $451.38K